[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337433-105":59,"doc-detail-337433-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pathogenesis-and-signaling-pathways-related-to-iodine-refractory-differentiated-thyroid-cancer","Pathogenesis and signaling pathways related to iodine-refractory differentiated thyroid cancer","","Review focused on the mechanisms driving iodine-refractory differentiated thyroid cancer (RAIR-DTC), a differentiated thyroid malignancy that fails to respond to conventional radioiodine therapy. RAIR-DTC evolution is linked to dedifferentiation events caused by alterations in thyroid oncogenes and signaling pathways, with markedly reduced or absent sodium/iodine symporter (NIS) expression. The work summarizes recent advances in RAIR-DTC pathogenesis and highlights molecular signaling routes as potential targets for future precision therapies, addressing the disease’s poor prognosis and limited current treatments.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pathogenesis-and-signaling-pathways-related-to-iodine-refractory-differentiated-thyroid-cancer/337433/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pathogenesis-and-signaling-pathways-related-to-iodine-refractory-differentiated-thyroid-cancer/337433.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What defines iodine-refractory differentiated thyroid cancer (RAIR-DTC)?","Question",{"text":112,"@type":113},"RAIR-DTC is determined when a lesion shows complete loss of iodine uptake during I131 therapy, progressively decreasing iodine uptake, heterogeneous iodine uptake, or limited benefit from radioiodine due to insufficient absorbed tumor dose. These criteria are described based on American Thyroid Association guideline indications.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do changes in signaling pathways contribute to RAIR-DTC progression?",{"text":117,"@type":113},"Alterations in key thyroid oncogenes or signaling pathways initiate tumor cell dedifferentiation, accompanied by reduced or virtually absent expression of the sodium/iodine symporter (NIS). This leads to impaired iodine uptake and radioiodine insensitivity.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is NIS central to both iodine uptake and RAIR-DTC resistance?",{"text":121,"@type":113},"NIS enables thyroid cells to uptake iodine for thyroid hormone synthesis and is required for effective radioactive I131 treatment. Mutations or degradation of NIS in the plasma membrane, including alterations in the SLC5A5 gene, can impair uptake and contribute to RAIR-DTC.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337433,1790660451,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","TYPE Review  \nPUBLISHED 19 January 2024  \nDOI 10.3389/fendo.2023.1320044  \nOPEN ACCESS  \nEDITED BY  \nMarek Dedecjus,  \nMaria Sklodowska Curie Institute of Oncology, Poland  \nREVIEWED BY John Morris,  \nUniversity of Cincinnati Medical Center, United States  \nBarbara Maria Jarzab,  \naria Skłodowska-Curie National Research Institute of Oncology, Poland  \n*CORRESPONDENCE Guangzhi Wang  \n[wanggz@dmu.edu.cn](wanggz@dmu.edu.cn)[ ](wanggz@dmu.edu.cn)Yongfu Zhao  \n [dl.zyf67@163.com](dl.zyf67@163.com)  \n†These authors have contributed equally to this work  \nRECEIVED 11 October 2023  \nACCEPTED 26 December 2023  \nPUBLISHED 19 January 2024  \nCITATION  \nZhao S, Zhao Y, Zhao Y and Wang G (2024) Pathogenesis and signaling pathways  \nrelated to iodine-refractory differentiated thyroid cancer.  \nFront. Endocrinol. 14:1320044 .  \ndoi: 10.3389/fendo.2023.1320044  \nCOPYRIGHT  \n© 2024 Zhao, Zhao, Zhao and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nPathogenesis and signaling pathways related to iodinerefractory differentiated thyroid cancer  \nSimeng Zhao †, Yuejia Zhao †, Yongfu Zhao* and Guangzhi Wang*  \nDepartment of Thyroid Surgery, The Second Hospital of Dalian Medical University, Dalian, China  \nThyroid cancer is the most common malignant neoplasm within the endocrine system and the ﬁeld of head and neck surgery. Although the majority of thyroid cancers, more than 90%, are well-differentiated thyroid carcinomas with a favourable prognosis, the escalating incidence of this disease has contributed to an increasing number of patients with a propensity for recurrent disease, rapid disease progression, and poor or no response to conventional treatments. These clinical challenges are commonly attributed to alterations in key thyroid oncogenes or signaling pathways, thereby initiating tumour cell dedifferentiation events, accompanied by reduced or virtually absent expression of the sodium/ iodine symporter (NIS) . As a result, the disease evolves into iodine-refractory differentiated thyroid cancer (RAIR-DTC), an entity that is insensitive to conventional radioiodine therapy. Despite being classiﬁed as a differentiated thyroid cancer, RAIR-DTC has an extremely poor clinical prognosis, with a 10-year survival rate of less than 10% . Therefore, it is of paramount importance to comprehensively elucidate the underlying pathogenesis of RAIR-DTC and providespeciﬁc targeted interventions. As the pathogenic mechanisms of RAIR-DTC remain elusive, here we aim to review recent advances in understanding the pathogenesis of RAIR-DTC and provide valuable insights for the development of future molecularly targeted therapeutic approaches.  \nKEYWORDS  \nRAIR-DTC, NIS, molecular mechanism, signaling pathway, targeted therapy  \n1 Introduction  \nThyroid cancer, the most common malignancy of the endocrine system, has shown an alarming increase in incidence and mortality (1) . Global data from 2018 revealed that there were approximately 567,233 new cases of thyroid cancer, accounting for 3.1% of all cancers studied. In addition, there were 41,071 deaths attributed to the disease, representing 0.4% of the total (2) . Although the majority of thyroid cancers (over 90%) are well-differentiated  \nFrontiers in Endocrinology 01 [frontiersin.org](frontiersin.org)  \npapillary or follicular carcinomas with a favourable prognosis (3), approximately 10% of differentiated thyroid cancers develop distant metastases (4) . More seriously, approximately one third of these metastatic cases exhibit an inability of thyroid cells to take up iodine, rendering them insensitive to radioio","cbCailMRKQRupkMD","https://ap.wps.com/l/cbCailMRKQRupkMD","pdf",414675,"English","# Introduction\n# Pathogenesis of RAIR-DTC\n## NIS regulation and iodine uptake failure\n## Signaling pathway alterations and dedifferentiation\n# Therapeutic targeting and future directions","[{\"question\":\"What defines iodine-refractory differentiated thyroid cancer (RAIR-DTC)?\",\"answer\":\"RAIR-DTC is determined when a lesion shows complete loss of iodine uptake during I131 therapy, progressively decreasing iodine uptake, heterogeneous iodine uptake, or limited benefit from radioiodine due to insufficient absorbed tumor dose. These criteria are described based on American Thyroid Association guideline indications.\"},{\"question\":\"How do changes in signaling pathways contribute to RAIR-DTC progression?\",\"answer\":\"Alterations in key thyroid oncogenes or signaling pathways initiate tumor cell dedifferentiation, accompanied by reduced or virtually absent expression of the sodium/iodine symporter (NIS). This leads to impaired iodine uptake and radioiodine insensitivity.\"},{\"question\":\"Why is NIS central to both iodine uptake and RAIR-DTC resistance?\",\"answer\":\"NIS enables thyroid cells to uptake iodine for thyroid hormone synthesis and is required for effective radioactive I131 treatment. Mutations or degradation of NIS in the plasma membrane, including alterations in the SLC5A5 gene, can impair uptake and contribute to RAIR-DTC.\"}]","Pathogenesis and signaling pathways related to iodine-refractory differentiated thyroid cancer | PDF",1790019118,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b714f60311abdf51398bbb7817cb6872.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ec98dd7c7dfe7ece5c5b57137d94ca87.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/264b274f281a34fd9c06edd757f6bbbe.webp",981,1386,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1bb9c47b9c303bbfa2cad60d09a06fde.webp",980,1385]